Total
0
Shares
Pharmadrug to acquire psychedelics company
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Entheon Biomedical (ENBI) has been approved for trading on the OTCQB Venture Market
  • Shares will trade on the OTCQB under the symbol ENTBF
  • Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States and throughout Canada
  • Entheon Biomedical Corp. (ENBI) is a biotechnology research and development company
  • Entheon Biomedical Corp. (ENBI) is up 2.22 per cent, trading at C$0.46 per share at 11 am ET

Entheon Biomedical (ENBI) has been approved for trading on the OTCQB Venture Market (OTCQB) effective May 5, 2021.

"We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we advance our DMT addiction therapy program toward human trials, continue R&D on our diagnostic and patient-monitoring platform, and scale up commercial availability of our subsidiary, HaluGen Life Science's Psychedelics Genetic Test, we are pleased to be gaining increased visibility and investor access within the U.S. market," said Timothy Ko, CEO of Entheon.

The shares will trade on the OTCQB under the symbol ENTBF. The company's shares will continue to trade on the Canadian Securities Exchange.

This U.S. listing will provide Entheon with access to a broader base of U.S. and international retail and institutional investors, providing increased access to data, transparency and liquidity.

Subject to obtaining all required regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

Entheon Biomedical Corp. (ENBI) is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N, N-dimethyltryptamine-based psychedelic therapeutic products to treat addiction and substance use disorders.

Entheon Biomedical Corp. (ENBI) is up 2.22 per cent, trading at C$0.46 per share at 11 am ET.

More From The Market Herald
VitalHub - President and CEO, Dan Matlow - The Market Herald Canada

" VitalHub (TSXV:VHI) to commence trading on the TSX

VitalHub (VHI) begins trading on the Toronto Stock Exchange on September 23, 2021.
BetterLife Pharma - CEO, Ahmad Doroudian. - The Market Herald Canada

" BetterLife (CSE:BETR) enrolls first patient in Interferon alpha-2b COVID-19 trial

The first patient has been enrolled in BetterLife’s (BETR) Interferon alpha-2b COVID-19 trial in Chile.
Clearmind Medicine (CSE:CMND) announces closing of private placement

" Clearmind Medicine (CSE:CMND) partners with The Hebrew University

Clearmind Medicine (CMND) has established a research and development partnership with the Yissum Research Development Company.
International Consolidated Uranium (TSXV:CUR) partners with Mars Investor Relations

" Algernon Pharmaceuticals (CSE:AGN) welcomes Dr. Mark Williams to the board

Algernon Pharmaceuticals (AGN) is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board of Directors.